Osprey Medical is a medical device company focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. We are a U.S.-based company with strong roots in Australia. Our core technology was developed at the Baker IDI Heart and Diabetes Institute in Melbourne, Australia.
Osprey Medical completed its initial public offering of CDIs (CHESS Depositary Interests) and began trading on the Australian Securities Exchange (“ASX”) on May 2, 2012 under the symbol "OSP". Ownership interests in Osprey Medical may be held in either CDIs or shares of common stock, but only CDIs may be traded on the ASX. Two CDIs are equal to one share of common stock.
Osprey Medical’s product specific labeling indications may vary by geography.